The announcement on Monday came after Ireland, Denmark, Norway and Iceland already moved to suspend the jab following blot-clotting issues, some of them fatal, in people who had used it.
The Netherlands said on Monday it had seen 10 cases of possible noteworthy adverse side-effects from the AstraZeneca vaccine, hours after the government put its vaccination programme on hold following reports of potential side-effects in other countries.
Meanwhile Denmark has reported “highly unusual” symptoms in a 60-year-old citizen who died from a blood clot after receiving the vaccine, the same phrase used on Saturday by Norway about three people under the age of 50 it said were being treated in hospital.
Iceland and Bulgaria had earlier suspended its use while Austria, along with Italy, have stopped using particular batches.
However France, Germany and the United Kingdom say they have no concerns about jab.
Prosecutors in the northern Italian region of Piedmont said on Monday they have seized a batch of 393,600 shots of the AstraZeneca Covid-19 vaccine following the death of a man hours after he had received the jab.
Piedmont’s regional government suspended use of the batch on Sunday after Sandro Tognatti, a 57-year-old music teacher, fell ill and died in circumstances that have not yet been clarified.
The European Medicines Agency has said that as of March 10, a total of 30 cases of blood clotting had been reported among close to five million people vaccinated with the AstraZeneca shot in the European Economic Area, which links 30 European countries.
The small number of reported side-effects in Europe have upset vaccination programmes already under pressure over slow rollouts and vaccine scepticism in some countries.
AstraZeneca Plc said earlier it had conducted a review covering more than 17 million people vaccinated in the European Union and the UK which had shown no evidence of an increased risk of blood clots.
That view was backed up on Monday by Professor Sir David Spiegelhalter, a statistician at University of Cambridge, who said the decision to pause the AstraZeneca vaccine rollout in some countries could be doing “more harm than good”.
He told BBC Radio 4’s World At One: “I think these pauses, I don’t think you can consider these as being cautious.
“They actually could be doing more harm than good.
“If it means there is a delay in rolling out the vaccine to people who would otherwise have a vaccine, then that will cause harm.”
He agreed there was no evidence that the Oxford jab increased risk of deep vein thrombosis (DVT) in any defined age group, gender, batch or in any particular country.
“I’ve looked at the AstraZeneca reports and they’ve said that 17 million jabs across the EU and the UK (had been administered) and they’ve had about 15 cases of deep vein thrombosis and 22 cases of pulmonary embolism reported,” he told the World At One.
“Doing some some sums, deep vein thrombosis happens to one in 1,000 people per year of all ages.
“So, out of those 17 million jabs, we would expect at least 17,000 of those people to get a deep vein thrombosis some time in the year.
“So that means that there will have been – and you can pretty well guarantee it – 350 people who have had an AstraZeneca jab then had a deep vein thrombosis in the week following that.
“I think what’s surprising is that only 15 have been reported as a possible adverse effect.”
The World Health Organization weighed in on Monday, appealing to countries not to pause vaccination campaigns after Indonesia also suspended use of AstraZeneca’s vaccine over safety fears.
“As of today, there is no evidence that the incidents are caused by the vaccine and it is important that vaccination campaigns continue so that we can save lives and stem severe disease from the virus,” WHO spokesman Christian Lindmeier said.
The WHO said that as of March 12, more than 300 million doses of Covid-19 vaccines had been administered around the world with no cases of death found to have been caused by any of them.